{"id":5220,"date":"2021-10-25T15:21:00","date_gmt":"2021-10-25T19:21:00","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=5220"},"modified":"2022-06-23T10:33:04","modified_gmt":"2022-06-23T14:33:04","slug":"bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/","title":{"rendered":"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors"},"content":{"rendered":"\r\n<p>PALO ALTO, CA \u2013 October 25, 2021 \u2014\u00a0BridgeBio Pharma, Inc. (Nasdaq: BBIO),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health\u2019s efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine\u00a0currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation and her work to promote workforce diversity.<\/p>\r\n\r\n\r\n\r\n<p>\u201cFrom her groundbreaking discovery of a new technology to help transplant patients, to her meaningful efforts to support and encourage diversity within biomedical sciences, Dr. Valantine\u2019s impact on our industry is far-reaching,\u201d said BridgeBio founder and CEO Neil Kumar, Ph.D. \u201cWe are proud to have Dr. Valantine join our board and we feel privileged to have the opportunity to learn from her as we work to build the next great genetic medicine company together.\u201d<\/p>\r\n\r\n\r\n\r\n<p>At the National Institutes of Health, Dr. Valantine served as the inaugural chief officer for scientific workforce diversity, and as a senior\u00a0investigator in the intramural research program at the National Heart, Lung, and Blood Institute from 2014 to 2020. Prior to that, she was a professor of cardiovascular medicine and the senior associate dean for diversity and leadership at Stanford.<\/p>\r\n\r\n\r\n\r\n<p>In collaboration with her colleagues at Stanford, Dr. Valantine co-invented the technology for\u00a0organ donor\u00a0derived cell-free DNA for diagnosis of transplant rejection, which is currently licensed and used\u00a0to monitor patients\u00a0for\u00a0early detection of acute organ rejection. Dr. Valantine also serves as the principal and founder of HAV LLC, a consulting company for diversity, equity and inclusion that she founded in January 2021. Dr. Valantine serves on the board of directors of Pacific Biosciences of California, Inc. and of CareDx, Inc. Dr. Valantine received her M.B.B.S., M.R.C.P. and M.D. at St. Georges Hospital\/London University.<\/p>\r\n\r\n\r\n\r\n<p>\u201cAs someone who has been focused throughout my career on improving patient outcomes, I am impressed and inspired by BridgeBio\u2019s commitment to helping people living with genetic diseases and cancers. I look forward to supporting the company in its efforts to develop meaningful medicines for patients around the world, and fostering an environment where diverse perspectives are heard and harnessed as we advance promising biomedical research for patients in need,\u201d said Dr. Valantine.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><\/p>\r\n\r\n\r\n\r\n<p>BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company\u2019s two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"http:\/\/bridgebio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Media Contact:<\/strong><br \/>Grace Rauh<br \/><a href=\"mailto:Grace.rauh@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Grace.rauh@bridgebiodev.wpengine.com<\/strong><\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Investor Contact:<\/strong><br \/>Katherine Yau<br \/><a href=\"mailto:katherine.yau@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>katherine.yau@bridgebiodev.wpengine.com<\/strong><\/a>\u00a0<br \/>(516) 554-5989<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, CA \u2013 October 25, 2021 \u2014\u00a0BridgeBio Pharma, Inc. (Nasdaq: BBIO),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health\u2019s efforts to promote diversity, [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-5220","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"people":false,"external_link":"","presentation":"","meta_short_title":"BridgeBio Appoints Hannah Valantine to Board of Directors","meta_description":"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors","meta_share_image":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Appoints Valantine as New Board Member | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Appoints Valantine as New Board Member | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-25T19:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T14:33:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Cybele Gouverneur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cybele Gouverneur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/\",\"name\":\"BridgeBio Appoints Valantine as New Board Member | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2021-10-25T19:21:00+00:00\",\"dateModified\":\"2022-06-23T14:33:04+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\"},\"description\":\"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\",\"name\":\"Cybele Gouverneur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"caption\":\"Cybele Gouverneur\"},\"url\":\"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Appoints Valantine as New Board Member | BridgeBio","description":"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Appoints Valantine as New Board Member | BridgeBio","og_description":"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/","og_site_name":"BridgeBio","article_published_time":"2021-10-25T19:21:00+00:00","article_modified_time":"2022-06-23T14:33:04+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Cybele Gouverneur","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Cybele Gouverneur","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/","name":"BridgeBio Appoints Valantine as New Board Member | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2021-10-25T19:21:00+00:00","dateModified":"2022-06-23T14:33:04+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7"},"description":"BridgeBio announced that it has added a new independent director to its board to promote diversity, equity, and inclusion in biomedical research. Learn more!","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversity-hannah-valantine-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7","name":"Cybele Gouverneur","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","caption":"Cybele Gouverneur"},"url":"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5220"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5220"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5220\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}